- Home
- RY vs MRK Comparison
RY vs MRK Comparison
Compare RY & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RY | MRK |
|---|---|---|
| Founded | 1864 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.4B | 268.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RY | MRK |
|---|---|---|
| Price | $168.35 | $107.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $162.00 | $114.86 |
| AVG Volume (30 Days) | 1.3M | ★ 11.5M |
| Earning Date | 02-26-2026 | 02-03-2026 |
| Dividend Yield | 2.68% | ★ 3.17% |
| EPS Growth | 25.07 | ★ 58.08 |
| EPS | ★ 10.04 | 7.56 |
| Revenue | $44,415,504,717.00 | ★ $64,235,000,000.00 |
| Revenue This Year | $16.04 | $1.97 |
| Revenue Next Year | $5.00 | $4.71 |
| P/E Ratio | $16.67 | ★ $14.21 |
| Revenue Growth | ★ 15.03 | 1.68 |
| 52 Week Low | $106.10 | $73.31 |
| 52 Week High | $174.61 | $112.90 |
Technical Indicators
Market Signals| Indicator | RY | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 53.62 |
| Support Level | $166.63 | $106.93 |
| Resistance Level | $169.94 | $111.97 |
| Average True Range (ATR) | 1.78 | 2.59 |
| MACD | -0.68 | -0.65 |
| Stochastic Oscillator | 51.62 | 16.83 |
Price Performance
Historical ComparisonAbout RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with around CAD 2.3 trillion in assets at the end of fiscal 2025. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).